A Randomized, Blinded, Parallel Group, Multi-center Dose-finding Study, to Assess the Efficacy, Safety and Tolerability of Different Doses of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection

Trial Profile

A Randomized, Blinded, Parallel Group, Multi-center Dose-finding Study, to Assess the Efficacy, Safety and Tolerability of Different Doses of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Sep 2017

At a glance

  • Drugs Tobramycin (Primary)
  • Indications Bronchiectasis
  • Focus Therapeutic Use
  • Acronyms iBEST-1
  • Sponsors Novartis
  • Most Recent Events

    • 26 Apr 2017 Planned End Date changed from 19 Jun 2018 to 10 Sep 2018.
    • 26 Apr 2017 Planned primary completion date changed from 19 Jun 2018 to 10 Sep 2018.
    • 14 Feb 2017 Planned End Date changed from 1 May 2018 to 19 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top